Intratumoral recombinant human interferon alpha‐2a and vincristine combination therapy in canine transmissible venereal tumour
Open Access
- 17 August 2018
- journal article
- research article
- Published by Wiley in Veterinary Medicine and Science
- Vol. 4 (4) , 364-372
Abstract
Canine transmissible venereal tumour (CTVT) is a naturally occurring contagious neoplasm of dogs located mainly on the external genitalia of both sexes. The course of vincristine chemotherapy, the most effective and practical therapy, is affected by the immune status of the host. The aim was to investigate recombinant human interferon alpha‐2a (rhIFNα‐2a) and vincristine for treatment ofCTVT. A total of 21 female dogs were included. In group I (n = 9), vincristine (0.025 mg/kg,IV) was administered weekly. In groupII(n = 6), dogs were injected intratumorally weekly with 1.5 millionIUrhIFNα‐2a. In groupIII(n = 6), rhIFNα‐2a and vincristine were combined. No tumour regression was observed after three injections of rhIFNα‐2a in groupIIand weekly vincristine was administered. The number of tumour infiltrating lymphocytes (TILs), mitotic figures and apoptotic cells were counted in subsequent incisional tumour biopsies. The Kaplan–Meier Method was used to analyse survival using complete tumour regression as the outcome and Breslow Test was used for comparison of survival curves. Differences inTILs, cell proliferation and apoptosis between groups were assessed by analysis of covariance. Complete regression was observed in all animals included. Mean duration of vincristine treatment for complete regression was shorter in groupII(3.50 weeks, 95%CI, 3.06–3.94,P < 0.05) and groupIII(3.17 weeks, 95%CI, 2.84–3.49,P < 0.01) compared to group I (5.11 weeks, 95%CI, 4.42–5.80). Vincristine and rhIFNα‐2a combination increasedTILs inCTVTbiopsies compared to vincristine treatment (P = 0.017) and vincristine treatment after rhIFNα‐2a (P = 0.049). Vincristine treatment after rhIFNα‐2a (GroupII;P < 0.001) and rhIFNα‐2a and vincristine combination (GroupIII;P < 0.001) decreased apoptosis. The results indicate that intratumoral rhIFNα‐2a treatment alone is not effective inCTVT. However, combination of rhIFNα‐2a and vincristine shortens the duration of treatment compared to vincristine therapy.Keywords
This publication has 38 references indexed in Scilit:
- Predictive factors for the regression of canine transmissible venereal tumor during vincristine therapyThe Veterinary Journal, 2010
- A Clinico‐pathological Study on the Effect of Vincristine on Transmissible Venereal Tumour in DogsJournal of Veterinary Medicine Series A, 2005
- Veterinary co‐operative oncology group – common terminology criteria for adverse events (VCOG‐CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0Veterinary and Comparative Oncology, 2004
- Canine transmissible venereal tumour: Cytogenetic origin, immunophenotype, and immunobiology. A reviewVeterinary Quarterly, 2003
- Treatment of Canine Hemangiosarcoma: 2000 and BeyondJournal of Veterinary Internal Medicine, 2000
- Treatment of Canine Hemangiosarcoma: 2000 and BeyondJournal of Veterinary Internal Medicine, 2000
- Low-Dose Oral Administration of Interferon-alpha for the Treatment of Immune-Mediated Keratoconjunctivitis Sicca in DogsJournal of Interferon & Cytokine Research, 1999
- Role of Lymphocytes in Spontaneous Regression of Experimentally Transplanted Canine Transmissible Venereal Sarcoma.Journal of Veterinary Medical Science, 1994
- Role of lymphocytes in dogs experimentally re-challenged with canine transmissible sarcoma.The Japanese Journal of Veterinary Science, 1989
- The effects of human interferon-alpha upon in vitro canine immune responsesVeterinary Immunology and Immunopathology, 1988